Search

everythinglearnresearchcommunity

for

Search:↓

Liposomal carriers for topical finasteride offer better targeting, reduced side effects, and less irritation compared to alcohol-based solutions, but availability and cost may limit their use. Minoxidil can dissolve in liposomal carriers, enhancing delivery and stability.

A healthy scalp barrier is crucial for hair growth, and ceramides may play a key role in maintaining it. The conversation suggests that focusing on scalp health, alongside treatments like Minoxidil, Finasteride, and RU58841, could improve hair follicle health.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

Topical RU58841 is discussed for hair loss treatment, with a focus on brands available in Europe that have low systemic absorption. Users suggest mixing your own solution to control vehicle and dosage, and mention different brands like Actifolic and Biolabshop.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

A 26-year-old man shared his positive results after 10 months of treating male pattern baldness using a regimen that includes Estradiol Enanthate, DHPA, Bicalutamide, Dutasteride, oral and topical Minoxidil, and a dermaroller. He experienced mild gynecomastia and reduced body hair as side effects but was satisfied with the outcome.

The conversation discusses using tretinoin for hair loss and whether applying SPF on the scalp is necessary if hair covers the treated areas. The user is considering this treatment despite having no completely bald patches.

Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.

The conversation discusses the potential positive effects of melatonin on hair growth. The original poster plans to try both oral and topical melatonin and is seeking recommendations for a good source.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

The user experiences irritation from alcohols in minoxidil and is considering alternatives like trichosol mixed with polyethylene glycol or DMSO. They seek advice on the best nonirritating option.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

The conversation discusses recommendations for using topical melatonin for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

The conversation is about finding the optimal concentration of topical melatonin for hair loss treatment. The user is considering making their own solution and is unsure whether a higher concentration is more effective for deactivating prolactin receptors.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The user is currently using 0.025% Pantostin but plans to switch to 0.1% Alfatradiol. They will also use high-dose Kx826, high-dose Minoxidil, and aggressive microneedling for hair regrowth.

People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.

User is using a homemade topical treatment with .015% finasteride, 5% minoxidil, and microneedling at .75mm depth. They also use 2% ketoconazole shampoo, various oils, and are considering increasing finasteride concentration due to mixed results.

A user shared their initial experiences with The Ordinary hair density serum, which contains Redensyl (taxifolin). They observed increased hair volume but also developed pimples, likely due to the serum stimulating sebaceous glands.

A user is considering a hair transplant in a "mohawk" pattern with scalp micropigmentation (SMP) on the sides and back, questioning its feasibility and appearance. Others discuss donor region quality, potential scarring, and alternative treatments like dutasteride and RU58841.

The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

The user is experiencing scalp itching from a PG ethanol base in their hair loss treatment, which includes 0.025% finasteride and 2.5% minoxidil, and is seeking alternatives without PG or ethanol. Suggestions include Zeuss non-PG foam and Ulo, which do not use PG or hydrocortisone.